DENVER - DaVita Inc . (NYSE: NYSE:DVA), a leading provider of kidney care services, has reported a robust first quarter, surpassing analyst expectations for both earnings per share (EPS) and revenue. The company's EPS for the quarter was $2.38, significantly higher than the analyst estimate of $1.92. Revenue also exceeded forecasts, coming in at $3.07 billion against an anticipated $3.01 billion.
The company's future outlook is equally promising, with DaVita projecting a full-year 2024 EPS range of $9.00 to $9.80, which edges above the consensus estimate of $9.01. This forward-looking guidance has resonated positively with investors, as evidenced by a 3% uptick in DaVita's stock following the announcement.
CEO Javier Rodriguez commented on the quarter's success, stating, "Through the first quarter, we continued building on the momentum generated through 2023, demonstrating operational discipline while continuing to find opportunities to invest, innovate and most importantly deliver clinical excellence."
DaVita's first-quarter performance also marked a significant improvement compared to the same period last year. The company's disciplined operational approach and strategic investments have been pivotal in driving this growth. Additionally, the company's efforts to streamline patient care costs and capitalize on favorable changes in treatment mix have contributed to the financial upswing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.